Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Tax Provisions (2021 - 2022)

Cartesian Therapeutics (RNAC) has disclosed Tax Provisions for 2 consecutive years, with -$288000.0 as the latest value for Q4 2022.

  • For Q4 2022, Tax Provisions fell 308.7% year-over-year to -$288000.0; the TTM value through Dec 2022 reached $15.4 million, down 3.81%, while the annual FY2025 figure was -$9.2 million, 3164.33% down from the prior year.
  • Tax Provisions hit -$288000.0 in Q4 2022 for Cartesian Therapeutics, up from -$321000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $15.8 million in Q3 2021 and bottomed at -$321000.0 in Q3 2022.